Pre-DD on re-purposed CNS products

Challenge: A Middle Eastern VC firm was interested in a US-based drug re-purposing company and asked Alacrita to perform a high level technical due diligence exercise to help the firm make an...
Learn More

Due Diligence on a bioinformatics platform to repurpose clinical-stage drugs

Challenge: Our client, a VC firm based in Dubai, was planning to invest in a US-based therapeutics company and asked Alacrita to perform a technical DD. The target company was using a proprietary...
Learn More

Due diligence on a reverse merger candidate with pipeline of IND-ready compounds

Challenge: A NASDAQ-listed biotech asked Alacrita to conduct a technical due diligence on a prospect reverse merger candidate. After screening numerous companies, our client identified a strong...
Learn More

Due diligence of first-in-class monoclonal antibody candidate drug

Challenge: A biopharma company required expert due diligence for a potential transaction with a clinical stage biotech focusing in inflammation and fibrosis. Alacrita was commissioned to provide an...
Learn More

Pre-due diligence of two early-stage assets: a nano-ADC & a small molecule

Challenge: A pharma company sought Alacrita's support in providing high-level go/no-go pre-due diligence of two early-stage strategic investment opportunities. The company had so far been focused on...
Learn More

Technical & commercial due diligence of two pipeline cell therapy products

Challenge: Alacrita was engaged due diligence and valuation support by a listed clinical stage biotechnology company. The biotech needed to benchmark the technical strengths and weaknesses of two...
Learn More

Due diligence on reinvestment in VC-backed biotech

Challenge: A family office invested in a European, VC-backed company sought Alacrita's expert view of re-investing in the company, following a Phase III trial failure in the immunology space. The...
Learn More

Expert witness to support pharma litigation process

Challenge: A major global law firm required an expert witness to support a litigation process between it client and another Big Pharma company.
Learn More

Due diligence on a AI-driven drug discovery platform

Challenge: A biotech company had developed an AI-driven drug discovery platform to discover phytocompounds and bioactives with the potential to impact human health. Alacrita was retained to conduct a...
Learn More

Ongoing DD support for research incubator and seed funder

Challenge: Our client, a research incubator, accelerator and seed funder within the biotechnology and life science arena, runs two programs in which companies/projects are selected through open...
Learn More

Valuation of Phase 3 Ready Alzheimer's Drug

Challenge: A clinical stage company developed two series of small molecules to treat Alzheimer Disease (AD) and other central nervous system (CNS) indications. Their lead asset aims for symptomatic...
Learn More

DD of a clinical stage therapeutic for rare neurodegenerative disorders

Challenge: A pharma company developing a first-in-class therapeutic to treat rare paediatric neurodegenerative disorders was nearing NDA approval in multiple indications and was ready to initiate...
Learn More
Content not found